Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease

Geroscience posits that cardiovascular disease (CVD) and other chronic diseases result from progressive erosion of the effectiveness of homeostatic mechanisms that oppose age-related accumulation of molecular damage. This hypothetical common root to chronic diseases explains why patients with CVD are often affected by multimorbidity and frailty and why older age negatively affects CVD prognosis and treatment response. Gerotherapeutics enhance resilience mechanisms that counter age-related molecular damage to prevent chronic diseases, frailty, and disability, thereby extending healthspan. Here, we describe the main resilience mechanisms of mammalian aging, with a focus on how they can affect CVD pathophysiology. We next present novel gerotherapeutic approaches, some of which are already used in management of CVD, and explore their potential to transform care and management of CVD. The geroscience paradigm is gaining traction broadly in medical specialties, with potential to mitigate premature aging, reduce health care disparities, and improve population healthspan. (J Am Coll Cardiol 2023;82:631-647) & COPY; 2023 by the American College of Cardiology Foundation.

Automated summary

Geroscience posits that CVD and other chronic diseases are caused by the progressive erosion of homeostatic mechanisms that counter age-related molecular damage. Gerotherapeutics enhance resilience mechanisms to prevent chronic diseases, frailty, and disability, thereby extending healthspan.